Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
INTERCEPT PHARMACEUTICALS, INC. (ICPT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/03/2023 |
4
| Freedberg Jared (General Counsel) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 771 shares
@ $10.5, valued at
$8.1k
|
|
06/16/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 1,246 shares
@ $12.04, valued at
$15k
|
|
05/25/2023 |
4
| Benatti Luca (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| SBLENDORIO GLENN (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| Gottesdiener Keith Michael (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| Fundaro Paolo (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| SANTINI GINO (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| ROSA-BJORKESON DAGMAR (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| Miller-Rich Nancy (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| BRADBURY DANIEL (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
05/25/2023 |
4
| AKKARAJU SRINIVAS (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 8,111 shares
@ $0 Granted 12,547 options to buy
@ $9.17, valued at
$115.1k
|
|
03/23/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 909 shares
@ $14.19, valued at
$12.9k
|
|
03/16/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 1,246 shares
@ $15.79, valued at
$19.7k
|
|
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/31/2023 |
4
| Venezia Rocco (Chief Accounting Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 9,800 shares
@ $0 Granted 16,000 options to buy
@ $18.4, valued at
$294.4k
|
|
01/31/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 14,700 shares
@ $0 Granted 24,000 options to buy
@ $18.4, valued at
$441.6k
|
|
01/31/2023 |
4
| Richardson Linda M (EVP & Chief Commercial Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 12,200 shares
@ $0 Granted 20,000 options to buy
@ $18.4, valued at
$368k
|
|
01/31/2023 |
4
| Freedberg Jared (General Counsel) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 12,200 shares
@ $0 Granted 20,000 options to buy
@ $18.4, valued at
$368k
|
|
01/31/2023 |
4
| Ford David A (Chief Human Resources Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 9,800 shares
@ $0 Granted 16,000 options to buy
@ $18.4, valued at
$294.4k
|
|
01/31/2023 |
4
| Durso Jerome Benedict (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 50,400 shares
@ $0 Granted 82,700 options to buy
@ $18.4, valued at
$1.5M
|
|
01/31/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Granted 14,700 shares
@ $0 Granted 24,000 options to buy
@ $18.4, valued at
$441.6k
|
|
01/03/2023 |
4
| Venezia Rocco (Chief Accounting Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 675 shares
@ $12.37, valued at
$8.3k
|
|
01/03/2023 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 718 shares
@ $12.37, valued at
$8.9k
|
|
01/03/2023 |
4
| Richardson Linda M (EVP & Chief Commercial Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 1,600 shares
@ $12.37, valued at
$19.8k
|
|
01/03/2023 |
4
| Freedberg Jared (General Counsel) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 718 shares
@ $12.37, valued at
$8.9k
|
|
01/03/2023 |
4
| Ford David A (Chief Human Resources Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 1,777 shares
@ $12.37, valued at
$22k
|
|
01/03/2023 |
4
| Durso Jerome Benedict (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 7,083 shares
@ $12.37, valued at
$87.6k
|
|
01/03/2023 |
4
| Berrey M Michelle (President, R&D & CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 765 shares
@ $12.37, valued at
$9.5k
|
|
12/23/2022 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 908 shares
@ $13.43, valued at
$12.2k
|
|
12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/23/2022 |
4
| Saik Andrew (EVP & CFO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 908 shares
@ $14.85, valued at
$13.5k
|
|
09/16/2022 |
4
| Berrey M Michelle (President, R&D and CMO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 1,246 shares
@ $17.14, valued at
$21.4k
|
|
09/06/2022 |
4
| Venezia Rocco (Chief Accounting Officer) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 429 shares
@ $18.06, valued at
$7.7k
|
|
|
|
|